Pharmacological characterization of the uroselective alpha-1 antagonist rec 15/2739 (SB 216469): Role of the alpha-1L adrenoceptor in tissue selectivity, part II

Journal of Pharmacology and Experimental Therapeutics

Volumn 281, Issue 3, 1997, Pages 1284-1293

  Testa, R ^a   Guarneri, L ^a   Angelico, P ^a   Poggesi, E ^a   Taddei, C ^a   Sironi, G ^a   Colombo, D ^a   Sulpizio, A C ^b   Naselsky, D P ^b   Hieble, J P ^b   Leonardi, A ^a  

^a Recordati SpA   (Italy)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 4 (4 NITROPHENYL) 3,5 PYRIDINEDICARBOXYLIC ACID [3 (4,4 DIPHENYL 1 PIPERIDINYL)PROPYL]AMIDE METHYL ESTER; 5 CHLORO N [2 (2 CYCLOPROPYLMETHOXYPHENOXY)ETHYL] ALPHA,ALPHA DIMETHYL 1H INDOLE 3 ETHANAMINE; 8 [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] 8 AZASPIRO[4.5]DECANE 7,9 DIONE; 8 [3 [4 (2 HYDROXYPHENYL) 1 PIPERAZINYL]PROPYLCARBAMOYL] 3 METHYLFLAVONE; 8 [3 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]PROPYLCARBAMOYL] 3 METHYLFLAVONE; 8 [3 [4 (5 CHLORO 2 METHOXYPHENYL) 1 PIPERAZINYL]PROPYLCARBAMOYL] 2 CYCLOHEXYL 3 METHYL 4H 1 BENZOPYRAN 4 ONE; 8 [3 [4 (5 CHLORO 2 METHOXYPHENYL) 1 PIPERAZINYL]PROPYLCARBAMOYL] 3 METHYLFLAVONE; ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; NORADRENALIN; PHENTOLAMINE; PRAZOSIN; REC 0 0232; REC 15 2615; REC 15 2627; REC 15 2636; REC 15 2731; REC 15 2784; REC 15 2841; RECEPTOR SUBTYPE; TAMSULOSIN; TERAZOSIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BINDING; DRUG POTENCY; DRUG SELECTIVITY; HYPOTENSION; KINETICS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE CONTRACTION; URETHRA STENOSIS;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; CHROMONES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION; URINARY TRACT;

EID: 14444284101     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. ARUNLAKSHANA, O. AND SCHILD, H. O.: Some quantitative uses of drug antagonism. Br. J. Pharmacol. Chemother. 14: 45-58, 1959.
2. 1-adrenoceptor subtypes mediate contraction in rabbit aorta and urethra. Eur. J. Pharmacol. 287: 153-161, 1995.
3. 1-adrenoceptor antagonists in dog prostate/blood pressure models. FASEB J. 10: A425, 1996.
4. BRESLIN, D., FIELDS, D. W., CHOU, T.-C., MARION, D. N., KANE, M., DARRACOTT VAUGHAN, E. JR. AND FELSEN, D.: , Medical management of benign prostatic hyperplasia: a canine model comparing the in vivo efficacy of alpha-1 adrenergic antagonists in the prostate. J. Urol. 149: 395-399, 1993.
5. BRUNE, M. E., BUCKNER, S. A., POLAKOWSKI, J., KERWIN, J. F. AND HANCOCK, A.: Pharmacological antagonism of α-adrenergic agonist induced increases in canine intraurethral pressure in vivo. Drug Dev. Res. 34: 267-275, 1995.
6. CAINE, M., PFAU, A. AND PERLBERG, S.: The use of alpha-adrenergic blockers in benign prostatic hyperplasia. Br. J. Urol. 48: 255-263, 1976.
7. CAMPBELL, S. F.: Structure-activity relationships for quinazoline α-adrenoceptor antagonists. X-Ray crystallography and drug action, ed. by A. S. Horn and C. J. De Rauter, pp. 347-366, Clarendon, Oxford, 1984.
8. 50) of an enzyme reaction. Biochem. Pharmacol. 22: 3099-3108, 1973.
9. DE LEAN, A., MUNSON, P. J. AND RODBARD, D.: Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am. J. Physiol. 235: E97-E102, 1978.
10. 1-adrenoceptor subtypes present in the human prostate. Life Sci. 54: 1595-1605, 1994.
11. 1a-adrenoceptor antagonist. Br. J. Pharmacol. 114: 24P, 1995.
12. 1-adrenoceptors in human prostate: implications for adrenergic classification. Mol. Pharmacol. 49: 209-215, 1996a.
13. 1A-adrenoceptor ? Br. J. Pharmacol. 118: 29P, 1996b.
14. 1c subtype. Mol. Pharmacol. 45: 703-708, 1994a.
15. FORRAY, C., CHIU, G., WETZEL, J. M., BARD, J. A., WEINSHANK, R. L., BRANCHEK, T. A., HARTIG, P. R. AND GLUCHOWSKI, C.: Effects of novel alpha-1C adrenergic receptor antagonists on the contraction of human prostatic smooth muscle, J. Urol. 151: 267A, 1994b.
16. GOETZ, A. S., LUTZ, M. W., RIMELE, T. J. AND SAUSSY, D. L.: Characterization of alpha-1 adrenoceptor subtypes in human and canine prostate membranes. J. Pharmacol. Exp. Ther. 271: 1228-1233, 1994.
17. 1C-Adrenergic antagonists and orthostatic hypotension. FASEB J. 8: A353, 1994.
18. HIEBLE, J. P., BOJCE, A. J. AND CAINE, M.: Comparison of the α-adrenoceptor characteristics in human and canine prostate. Fed. Proc. 45: 2609-2614, 1986.
19. HIEBLE, J. P., BYLUND, D. B., CLARKE, D. E., EIKENBURG, D. C., LANGER, S. Z., LEFKOWITZ, R. J., MINNEMAN K. P. AND RUFFOLO, R. R. JR.: International Union of Pharmacology X. Recommendation for Nomenclature of α1-adrenoceptors: Consensus update. Pharmacol. Rev. 47: 267-270, 1995.
20. 1-adrenoceptor subtypes in the rabbit prostate. J. Auton. Pharmacol. 15: 271-278, 1995.
21. HIRASAWA, A., SHIBATA, K., HORIE, K., TAKEI, Y., OBIKA, K., TANAKA, T., MURAMOTO, N., TAKAGAKI, K., YANO, Y. AND TSUJIMOTO, G.: Cloning, functional expression and tissue distribution of human αjc-adrenoceptor splice variants. FEBS Lett. 363: 256-260, 1995.
22. 1-Adrenoceptor subtypes mediating contraction of the smooth muscle in the lower urinary tract and prostate of rabbits. Naunyn-Schmiedeberg's Arch. Pharmacol. 330: 16-21, 1985.
23. 1-adrenoceptor antagonists on prostatic pressure and blood pressure in the anesthetized dog. Urology 44: 52-57, 1994.
24. 1-adrenoceptors: binding, functional and in vivo studies. Br. J. Pharmacol. 118: 871-878, 1996a.
25. 1-adrenoceptors. XIIth Congress of the European Association of Urology, pp. 29, September 1-4, 1996b, Paris.
26. 1-adrenoceptor subtypes involved in adrenergic contractions of dog blood vessels. Br. J. Pharmacol. 112: 1167-1173, 1994.
27. LEONARDI, A., MOTTA, G., RIVA, C. AND TESTA, R.: Derivati benzopiranici e benzotiopiranici. IT Patent MI92A000408, US Patents 5,403,842 (1995); 5,474,994 (1995); 5,605,897 (1997).
28. LEONARDI, A., RIVA, C., DE TOMA, C., BOI, C., PENNINI, R. AND SIRONI, G.: Synthesis and pharmacological evaluation of new indole derivatives structurally related to thymoxamine. Eur. J. Med. Chem. 29: 551-559, 1994.
29. LEONARDI, A., MOTTA, G., BOI, C. AND TESTA, R.; New quinazolinyl-amino derivatives useful as alpha-1 adrenoceptor blockers for treating arterial hypertension and prostatic benign hyperplasia etc. International Patent Application WO 95/25726 (1995).
30. LEONARDI, A., HIEBLE, J. P., GUARNERI, L., NASELSKY, D. P., POGGESI, E., SIRONI, G., SULPIZIO, A. C. AND TESTA, R.: Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): Role of the alpha-1L adrenoceptor in tissue selectivity. Part I. J. Pharmacol. Exp. Ther. 281: 000-000, 1997.
31. LEPOR, H.: Medical therapy for benign prostatic hyperplasia. Urology 42: 483-501, 1993.
32. 1A-adrenoceptor in the human prostate. J. Urol. 154: 2096-2099, 1995.
33. 1C-adrenoceptor: Functional characterization in prostate. Br. J. Pharmacol. 107: 327P, 1992.
34. 1A-adrenoceptor mediating contraction of rat epididymal vas deferens, rat hepatic portal vein and human prostate distinguished by the antagonist RS 17053. Br. J. Pharmacol. 119: 407-415, 1996.
35. MARUYAMA, K., FUKLTOMI, J., CHIBA, T., YAMAGUCHI, M., TAKEDA, M., HATTORI, K. AND NAGATOMO, T.: 2 Distinct alpha(1)-adrenoceptor subtypes in the human prostate. Assessment by radioligand binding assay using [3H]prazosin. Gen. Pharmacol. 27: 1377-1381, 1996.
36. MONDA, J. M. AND OESTERLING, J. E.: Medical treatment of benign prostatic hyperplasia: 5-reductase inhibitors and α-adrenergic antagonists. Mayo Clin. Proc. 68: 670-679, 1993.
37. 1-adrenoceptors in vascular smooth muscle. Br. J. Pharmacol. 99: 197-201, 1990.
38. 1-adrenoceptor subtypes in the human prostate: functional and binding studies. Br. J. Urol. 74: 572-578, 1994.
39. 1-adrenoceptors. Pharmacol. Commun. 6: 23-28, 1995.
40. 1-adrenoceptor antagonist, JTH-601: Comparison with prazosin. Eur. J. Pharmacol. 300: 155-157, 1996.
41. 1-adrenoceptor subtypes in rabbit thoracic aorta. Br. J. Pharmacol. 108: 1071-1076, 1993.
42. POIRIER, M., RIFFAUD, J., LACOLLE, Y. AND DUPONT, C.: Effects of five alpha-blockers on the hypogastric nerve stimulation of the canine lower urinary tract. J. Urol. 140: 165-167, 1988.
43. PRICE, D. T., SCHWINN, D. A., LOMASNEY, J. W., ALLEN, L. F., CARON, M. G. AND LEFKOWITZ, R. J.: Identification, quantification, and localization of mRNA for three distinct alphal adrenergic receptor subtypes in human prostate. J. Urol. 150: 546-551, 1993.
44. SAUSSY, D. L., GOETZ, A. S., QUEEN, K. L., KING, H. K., LUTZ, M. W. AND RIMELE, T. J.: Structure activity relationship of a series of buspirone analogs at alpha-1 adrenoceptors: Further evidence that rat aorta alpha-1 adrenoceptors are of the alpha-1D-subtype. J. Pharmacol. Exp. Ther. 278: 136-144, 1996.
45. 1-Adrenoceptor subtypes in the bovine prostate and human benign prostatic hypertrophy. J. Urol. 149: 241A, 1993.
46. 1-drenoceptor subtypes in prostate and prostatic urethra of rat, rabbit, dog and man. Eur. J. Pharmacol. 249: 307-315, 1993.
47. 1-antagonist selective for the lower urinary tract: in vivo studies. Neurourol. Urodyn. 13: 471-473, 1994a.
48. 1-antagonist selective for the lower urinary tract: In vitro studies. Neurourol. Urodyn. 13: 473-474, 1994b.
49. 1-adrenoceptor antagonist. Pharmacol. Commun. 6: 79-86, 1995.
50. 1-antagonist selective for the lower urinary tract, on noradrenaline-induced contraction of human prostate and mesenteric artery. J. Pharmacol. Exp. Ther. 277: 1237-1246, 1996a.
51. 1L-AR subtype. Neurourol. Urodyn. 15: 346-347, 1996b.
52. VARGAS, H. M. AND GORMAN, A. J.: Vascular alpha-1 adrenergic receptor subtypes in the regulation of arterial pressure. Life Sci. 57: 2291-2308, 1995.
53. WILDE, M. I., FITTON, A. AND MCTAVISH, D.: Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs 45: 410-429, 1993.